The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Issue of Debt

17 Dec 2012 09:56

RNS Number : 6721T
GlaxoSmithKline Capital PLC
17 December 2012
 



Publication of Final Terms

 

The following final terms dated 14 December 2012 (the "Final Terms") in respect of the Notes (as defined below) are available for viewing:

GlaxoSmithKline Capital plc issue of:

£600,000,000 3.375 per cent. Notes due 2027; and

£800,000,000 4.250 per cent. Notes due 2045,

in each case guaranteed by GlaxoSmithKline plc and issued under the £15,000,000,000 Euro Medium Term Note Programme (the "Notes").

To view the Final Terms in full, please paste the following URLs into the address bar of your browser.

 

http://www.rns-pdf.londonstockexchange.com/rns/6721T_-2012-12-17.pdf

 http://www.rns-pdf.londonstockexchange.com/rns/6721T_1-2012-12-17.pdf

Copies of the Final Terms have been submitted to the National Storage Mechanism and will shortly be available for viewing at:

http://www.morningstar.co.uk/uk/NSM.

 

For further information, please contact:

GlaxoSmithKline plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

 

Enquiries:

UK Media enquiries:

David Mawdsley

Sarah Spencer

(020) 8047 5502

(020) 8047 5502

 

European Analyst/Investor enquiries:

Sally Ferguson

Gary Davies

Ziba Shamsi

(020) 8047 5543

(020) 8047 5503

(020) 8047 3289

BASIS ON WHICH YOU MAY ACCESS THE FINAL TERMS AND BASE PROSPECTUS

Please note that the information contained in the Final Terms and the Base Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms is not addressed. Prior to relying on the information contained in the Final Terms or the Base Prospectus you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirements.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IODBKODQCBDKOBD

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.